ElliotNorryMDFACP

Gastroenterology

Adaptimmune, Chief Medical Officer

Dr. Norry is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Sidney Kimmel Medical College at Thomas Jefferson University/TJUHFellowship, Gastroenterology, 1993 - 1995
Temple University HospitalResidency, Internal Medicine, 1989 - 1992
New York University School of MedicineClass of 1989

PubMed

50 citations
Autologous T cell therapy for MAGE-A4solid cancers in HLA-A*02patients: a phase 1 trial.
David S Hong, Brian A Van Tine, Swethajit Biswas, Cheryl McAlpine, Melissa L Johnson
Nature Medicine. 2023-01-01
8 citations
Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors.
David S Hong, Marcus O Butler, Russell K Pachynski, Ryan Sullivan, Partow Kebriaei
Frontiers in Oncology. 2022-01-01
21 citations
Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10advanced non-small cell lung cancer.
George R Blumenschein, Siddhartha Devarakonda, Melissa Johnson, Victor Moreno, Justin Gainor
Journal for Immunotherapy of Cancer. 2022-01-01

Journal Articles

Fludarabine and Neurotoxicity in Engineered T-cell Therapy
Elliot Norry, Crystal L Mackall, Nature

Data from Cohort 1 of SPEARHEAD-1 Trial at CTOS Continue to Support BLA Submission for Afami-Cel in Synovial Sarcoma - Response Rate and Durability Remain ConsistentNovember 18th, 2022
Adaptimmune Reports Positive Results from Its Pivotal SPEARHEAD-1 Trial in Patients with Synovial Sarcoma and MRCLS at CTOSNovember 11th, 2021
Adaptimmune to Present Data Updates at Upcoming CTOS and SITC MeetingsOctober 5th, 2021
Join now to see all